⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611 | 0.78 | — | — | |
| SCHEMBL1771685 | 0.78 | CCR1 (0.71) | — | |
| SCHEMBL3587946 | 0.78 | — | — | |
| SCHEMBL30421349 | 0.78 | — | — | |
| Formaldehyde SCHEMBL6294564 | 0.77 | CCR1 (0.60) | — | |
| Hydrogen Sulfide SCHEMBL20214420 | 0.76 | — | — | |
| SCHEMBL17822110 | 0.76 | — | — | |
| Ammonia Solution, Strong SCHEMBL18983640 | 0.76 | — | — | |
| SCHEMBL184761 | 0.76 | — | — | |
| Bromide SCHEMBL5437785 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917925-B1 | PYRAZOLOPYRIDINES AND TRIAZOLOPYRIDINES AS A2A / A2B INHIBITORS | INCYTE CORP (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4304713-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | claimed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | claimed |
| US-11673894-B2 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | claimed |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | claimed |
| US-11390624-B2 | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2022-07-19 | — | — | US | claimed |
| EP-4025575-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| EP-4025572-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| EP-3917925-A1 | PYRAZOLOPYRIDINES AND TRIAZOLOPYRIDINES AS A2A / A2B INHIBITORS | Incyte Corporation (US) | 2021-12-08 | — | — | EP | claimed |
| EP-1246619-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | claimed |
| US-6514970-B1 | Pyrrolidines such as benzo(b)thiophene-2-carboxylic acid ((S)-1-((S)-1-(4-(1-benzyl-piperidin-4-yloxy)-3-chloro-benzyl)-pyrrolidin-3 -ylcarbamoyl)-3- methyl-butyl)-amide | SMITHKLINE BEECHAM CORPORATION | 2003-02-04 | — | — | US | claimed |
| EP-1246619-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-09 | — | — | EP | claimed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2001045700-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-28 | — | — | WO | claimed |
| EP-0664291-B1 | PYRIMIDINE COMPOUND | UBE INDUSTRIES (JP) | 2000-07-19 | — | — | EP | claimed |
| CN-1040322-C | Pyrimidines compounds | UBE INDUSTRIES (JP) | 1998-10-21 | — | — | CN | claimed |
| US-5610303-A | MONOAMIDE OXIDASE INHIBITORS | UBE INDUSTRIES, LTD. (JP) | 1997-03-11 | — | — | US | claimed |
| EP-0664291-A1 | PYRIMIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 1995-07-26 | — | — | EP | claimed |
| CN-1088207-A | pyrimidine compounds | UBE INDUSTRIES (JP) | 1994-06-22 | — | — | CN | claimed |